| http://www.w3.org/ns/prov#value | - with shareholders, Chiron Corporation (Novartis' predecessor) and then Novartis pushed the drug for unapproved uses, such as diseases other than cystic fibrosis, or for patients with cystic fibrosis that did not meet the specific parameters as laid out by the FDA ruling.
|
